80-Year-Old Beats Melanoma After Groundbreaking mRNA Vaccine Trial Success

An 80-year-old woman diagnosed with melanoma in 2020 remains cancer-free after taking part in a groundbreaking clinical trial. Connie Franciosi received a personalised mRNA vaccine combined with the immunotherapy drug Keytruda, a treatment that has shown remarkable success in extending survival rates for high-risk patients. Franciosi underwent surgery to remove her melanoma but faced a high risk of the cancer returning. She then joined a trial testing a new approach: a custom mRNA vaccine designed to target her specific tumour, used alongside Keytruda.

The results, presented at the American Society of Clinical Oncology conference and published in the *Journal of Clinical Oncology*, revealed significant improvements. After five years, 92% of patients on the combined therapy were still alive, compared to 71% of those receiving Keytruda alone. Additionally, 68.8% of the combination group remained cancer-free, while only 49.1% of the Keytruda-only group did. Melanoma, a form of skin cancer, is diagnosed in around 112,000 people in the U.S. each year, leading to roughly 8,500 deaths. Early detection improves outcomes, but advanced cases can be difficult to treat effectively.

Franciosi’s case highlights the potential of personalised mRNA vaccines in cancer treatment. The trial’s findings suggest that combining this technology with immunotherapy could offer long-term benefits for patients at high risk of recurrence. Researchers continue to explore how such therapies might transform care for other challenging cancers.